TNFRSF11A and chondroblastoma: The expression of RANKL in chondroblastoma cells has opened new avenues for treatment with denosumab, a monoclonal antibody that inhibits the RANK/RANKL pathway and shows effectiveness in controlling both local and metastatic tumors.